EdgeTestMarket TodayOptions TodayIPO
Start free

KIMSKrishna Institute of Medical Sciences Limited

Rs 669.6▲ +0.67%
Market closedEquity EOD 26 Oct
Compare
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.33.2% up the range
Rs 576Rs 858
KIMS price
Daily candles, adjusted for splits and bonus issues so a corporate action does not show as a crash. Pick a window from one month to the full history, add indicators, or open it full screen.
EOD 26 Oct
IndicatorsVolume

Loading KIMS price...

At a glance
Each figure is shown against the company's sector (the track: the dot is this company, the tick is the sector middle) and, where we hold the yearly filings, against its own recent years (the small trend line).
Market capWhat the whole company is worth on the stock market today: share price times the number of shares. It measures size, not quality.
Rs 28,123 cr
Larger than 63% of 19 peers
sector middle Rs 9,487 cr
P/EPrice to earnings: how many rupees investors pay for each rupee of profit the company made over the last twelve months. Compare it with similar companies rather than reading it alone.
131.3x
Higher than 88% of 17 peers
sector middle 52.9x
Price to bookPrice to book: the share price divided by the shareholders' money per share in the latest balance sheet. Around 1 means the market values the company close to its book value.
12.5x
Highest of 18 peers
sector middle 5.6x
ROEReturn on equity: the year's profit as a percentage of the shareholders' money in the business. It shows how much the company earns on what its owners have put in.
7.6%
Lower than 71% of 17 peers
sector middle 12.1%
FY23 18.9%FY26 9.5%
ROCEReturn on capital employed: operating profit as a percentage of all the long-term money in the business, owners' and lenders'. It shows how well the company uses its capital, whatever the mix of debt.
8.2%
Lower than 83% of 18 peers
sector middle 12.4%
FY23 19.5%FY26 8.2%
Debt to equityBorrowings divided by shareholders' money. 0 means no borrowings; 1 means it owes as much as its owners have put in. Not shown for banks and lenders, whose borrowing is their business.
1.27
Highest of 18 peers
sector middle 0.21
FY23 0.35FY26 1.27
Dividend yieldDividends paid over the last year as a percentage of the company's market value: roughly what Rs 100 of shares paid out in cash.
0.7%
Higher than 89% of 18 peers
sector middle 0.1%
Sales growthHow much the latest quarter's sales grew against the same quarter a year earlier.
+35.3%
Higher than 88% of 16 peers
sector middle +19.4%
FY24 13.7%FY26 28.7%

Peers are the listed companies in the exchange's own industry group: Hospital. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

What the numbers say
Short lines written by fixed rules from the company's own filings and shareholding. A line appears only when the figures cross the rule (for example sales growing three years running), and each names the numbers behind it. Nothing here is a view on whether to own the share.

Latest quarterIn the quarter to June 2026 (results filed 3 Aug 2026), sales rose 35.3% from a year earlier to Rs 1,180 cr and profit fell 56.0% to Rs 37.4 cr.

Going well
  • Sales grew 3 years running (Rs 2,198 cr in FY23 to Rs 3,905 cr in FY26).
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
Worth watching
  • Operating margin fell from 27.5% in FY23 to 20.5% in FY26.
  • Debt to equity rose 3 years running (0.35 to 1.27).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

How the share moved on results
For each quarterly result we hold: the change from the share's close on the last trading day before the filing to its close on the first trading day after it. Results can land during market hours or after the close, and this window covers both. It shows what happened, not what will happen next time.

Over the last 18 results, the share rose on 11 and fell on 7, and moved by 3% or more on 4.

Q2 FY22Q3 FY23Q3 FY24Q3 FY25Q1 FY27

Q1 FY27: results filed 3 Aug 2026. The share went from its close on 31 Jul 2026 to its close on 4 Aug 2026 -1.09%.

Where every Rs 100 of sales goes
From the company's own yearly results. Each year is scaled to that year's sales, so you compare shares, not size: how much went on running costs, depreciation, interest and tax, and how much was left as profit.
4 financial years
Sales, last 12 months
Rs 4,213 Cr
Profit, last 12 months
Rs 194 Cr
Earnings per share
Rs 5.1
Profit growth (qtr, YoY)
-56.00%

Of every Rs 100 of sales in FY26, Rs 79 went on running costs, Rs 7.3 on depreciation, Rs 5.2 on interest and Rs 2.4 on tax; Rs 6.2 was left as profit.

FY23
73
17
FY24
74
13
FY25
74
14
FY26
79
7.3
Sales (Rs 100)Other incomeOther gainsRunning costsDepreciationInterestTaxProfit

Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.

How fast it has grown
Compound growth per year in sales, profit and earnings per share between financial years, from the company's own results. A span appears only if our filings cover both ends of it.
Sales
3 yrs
+21.1%/yr
Latest qtr
+35.3%
Profit
3 yrs
-12.9%/yr
Latest qtr
-56.0%

Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.

Health check, year by year
Margins, returns, debt and interest cover for each financial year. Each row is coloured against this company's own usual level, so you see what is improving and what is slipping.
MeasureFY23FY24FY25FY26
Sales growthSales against the previous financial year.-13.7%21.5%28.7%
Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales.27.5%25.6%25.8%20.5%
Net marginProfit after everything, per Rs 100 of sales.16.6%13.5%13.7%6.2%
ROEProfit as a percentage of shareholders' money (from the March balance sheet).18.9%16.1%17.1%9.5%
ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'.19.5%14.9%13.2%8.2%
Debt to equityBorrowings divided by shareholders' money. Lower is safer.0.35x0.65x1.06x1.27x
Interest coverHow many times operating profit covers the interest bill. Higher is safer.16.9x10.8x7.2x2.6x

Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).

What it owns, and how that is paid for
Straight from the March balance sheet in the company's annual filing. Both bars are the whole balance sheet: what the company owns, and where the money for it came from.
as at 2026-03-31

At FY26 it owned Rs 7,759 Cr of assets. Its owners funded 33% of that and borrowings 42%.

What it owns
62%
24%
Plant, property and projects4,792 Cr
Goodwill and intangibles396 Cr
Investments16 Cr
Inventory97 Cr
Owed by customers554 Cr
Cash and bank75 Cr
Everything else1,829 Cr
How that is paid for
33%
42%
21%
Shareholders2,559 Cr
Borrowings3,244 Cr
Owed to suppliers323 Cr
Other liabilities1,633 Cr
Cash and equivalents
Rs 55 Cr
Net debt
Rs 3,174 Cr
Current ratio
0.76x
short-term assets per rupee due soon
Book value / share
Rs 54
Return on assets
2.5%
EV / EBITDA
38.3x

From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.

Where the cash went
Profit is an accounting figure; cash flow is what actually moved. Cash from running the business, plus or minus what was spent on or received from investments, plus or minus what came from or went to lenders and shareholders, equals the change in cash.

In FY26 the business itself brought in Rs 511 Cr, spent Rs 1,428 Cr on plant and equipment, and cash fell by Rs 1 Cr over the year.

From running the business
+511 Cr
Spent on or received from investing
-1,452 Cr
From or to lenders and shareholders
+940 Cr
Net change in cash
-1 Cr
Cash from operations for every Rs 100 of profit
Rs 118
FY23
Rs 155
FY24
Rs 140
FY25
Rs 211
FY26

Rs 100 or more means every rupee of reported profit arrived as cash.

Full financial year to 2026-03-31, from the company's cash flow statement.

Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Hospital · 28
P/E131.29vs 52.93 median
Cheapest: JLHL 8.84Priciest: LOTUSEYE 1419.5
Net margin4.61%vs 10.23% median
Lowest: LOTUSEYE 0.26%Highest: MAXHEALTH 16.73%
Revenue growth35.33%vs 19.39% median
Lowest: INDRAMEDCO 11.26%Highest: NH 78.05%
Compared against
AATMAJABHAGARWALEYEAPOLLOHOSPARTEMISMEDASTERDMDRAGARWQFORTISGKSLGPTHEALTHHCGINDRAMEDCOJLHLKMCSHILLOTUSEYEMAITREYAMANIPALHOSMAXHEALTHMEDANTAMOMSBELIEFNEPHROCARENHPARKHOSPSRAINBOWSANGANISHALBYUNIHEALTHYATHARTH

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

Peers side by side
Every company in the same NSE industry group that we hold figures for, largest first. Tap any heading to sort by it. The same figures as the At a glance tiles, worked out the same way for every company.
Hospital · 20 shown
Company
APOLLOHOSP
Apollo Hospitals Enterprise Limited
1.13 L cr54.0x11.9x21.8%19.5%0.578.2%+20.6%0.26%
MAXHEALTH
Max Healthcare Institute Limited
81,266 cr56.0x7.6x13.6%12.7%0.3216.7%+16.7%0.18%
MANIPALHOS
Manipal Health Enterprises Limited
73,581 cr--------
FORTIS
Fortis Healthcare Limited
55,467 cr52.9x5.6x10.5%12.0%0.2811.3%+17.5%0.14%
NH
Narayana Hrudayalaya Ltd.
33,971 cr41.4x7.5x18.0%11.4%1.079.0%+78.0%0.27%
ASTERDM
Aster DM Quality Care Limited
33,523 cr104.9x7.3x7.5%10.2%0.157.4%+21.6%0.16%
MEDANTA
Global Health Limited
32,575 cr58.6x8.2x13.9%15.1%0.3011.8%+26.5%0.04%
KIMS
Krishna Institute of Medical Sciences Limited
28,123 cr131.3x12.5x7.6%8.2%1.274.6%+35.3%0.74%
AGARWALEYE
Dr. Agarwal's Health Care Limited
15,065 cr102.2x7.4x8.7%9.7%0.078.4%+26.0%0.01%
RAINBOW
Rainbow Childrens Medicare Limited
11,802 cr41.3x7.2x17.4%16.8%0.0015.9%+33.2%0.26%
PARKHOSPS
Park Medi World Limited
9,487 cr-4.7x-18.1%0.11--0.00%
YATHARTH
Yatharth Hospital & Trauma Care Services Limited
8,924 cr49.3x4.9x9.7%11.0%0.1413.1%+52.3%0.00%
HCG
Healthcare Global Enterprises Limited
8,508 cr367.6x6.4x2.4%6.9%0.651.3%+13.4%0.00%
ARTEMISMED
Artemis Medicare Services Limited
4,547 cr40.0x4.9x12.1%13.7%0.2410.2%+12.7%0.13%
INDRAMEDCO
Indraprastha Medical Corporation Limited
2,750 cr20.8x3.7x25.4%30.7%0.0012.3%+11.3%1.49%
JLHL
Jupiter Life Line Hospitals Limited
1,658 cr8.8x1.1x12.1%13.8%0.3312.0%+18.2%0.40%
GKSL
Gujarat Kidney And Super Speciality Limited
1,400 cr70.8x5.5x6.6%8.6%0.0616.6%-0.00%
SHALBY
Shalby Limited
1,240 cr32.9x1.2x3.7%7.9%0.543.2%+11.7%0.00%
GPTHEALTH
GPT Healthcare Limited
1,066 cr22.6x4.0x17.6%16.4%0.069.6%+17.8%1.92%
LOTUSEYE
Lotus Eye Hospital and Institute Limited
236 cr1419.5x3.9x0.2%1.1%0.190.3%+26.2%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
4 years · 20 quarters
Full financial years - the long arc of the business.
Sales growth
+21.1%
a year, 3 years
Profit growth
-12.9%
a year, 3 years
Operating margin
20.5%
latest year
Sales by financial yearRs 3,905 Cr
Net profit by financial yearRs 242 Cr
FY234 full years · hover a yearFY26

Operating margin has gone from 27.5% to 20.5% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.

Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 26 Oct
RSI (14) - momentum
28.8Oversold
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
50.8%Near average
today 50.8%20d avg 52.5%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50-DMA
-10.68%
vs 200-DMA
-7.50%
1-month
-16.10%
3-month
-16.07%
1-year
-8.75%
Realized vol (30d)
26.6%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on KIMS?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.